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Abstract
Background: Tumor infiltrating B cells (TiBc) have not yet been investigated in detail. This may at least in part be due to
technical difficulties. Here we describe a straightforward and reproducible method to isolate and culture TiBc from primary
colorectal carcinomas (CRC).
Methods/Results: TiBc cultures were generated by Epstein-Barr virus (EBV) immortalization. With this method, monoclonal
TiBc cultures were obtained for 14/19 CRCs. As assessed by flow cytometry and ELISA, TiBc showed an activated
immunophenotype (CD23
+, CD80
+) and produced immunoglobulin (Ig; IgG secretion in 55% of the cultures). In functional in
vitro analysis, most of the IgGs specifically bound to allogeneic CRC target cells. These data suggest that TiBc are antigen-
experienced and thus may exhibit functionality in situ. Additionally, mini-cultures generated from 12 further CRCs revealed
TiBc outgrowth exclusively in the presence of EBV.
Conclusion: In summary, this simple method provides a cellular tool and our data set the stage for analysing the bivalent
role of TiBc; being antigen-presenting cells on the one hand and tumor-specific antibody producers on the other.
Additionally, the generation of long-term TiBc cultures and their monoclonal Ig may serve to identify novel tumor-specific
antigens.
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Introduction
Lymphocytes are major components of mononuclear cells
infiltrating human malignant tumors. Their positive prognostic
relevance is well established [1–3]. Recent studies focused on T cells,
for they are believed to have the greatest antitumoral potential [4].
Indeed, a dense infiltrate of CD8+ cells was shown to correlate with
prolonged survival of colorectal carcinoma (CRC) patients [5,6].
However, tumor-infiltrating B cells (TiBc) may play an
important role, too. They are considered to be positive regulators
of immunity often collaborating with T cells to generate potent,
unrelenting immune responses [7]. Beside their antibody (Ab)
producing capacity, they enhance T cell responses by secreting
stimulatory cytokines and chemokines, or by serving as local
antigen-presenting cells (APCs).
The tumor entity in which most efforts have been undertaken in
this regard is breast cancer. There, TiBc are present in about 24%
of tumors and comprise up to 40% of lymphocytic infiltrates [8,9].
They have been shown to undergo antigen-driven clonal prolifer-
ation and affinity maturation in situ [10]. Very recently, in a large
patient cohort of different histological and biological subtypes,
Mahmoud and colleagues provided evidence for a favorable
outcome when high numbers of CD20
+ TiBc are present. Of note,
this prognostic value was independent from any clinicopathological
marker [11]. So far, very few studies assessed the functional
relevance of TiBc and the antibodies produced thereof. Using
recombinant Ab cloning techniques, Hansen et al. reported an
antigen-driven humoral immune response directed against b-actin
exposed on apoptotic mammary carcinoma cells [12]. Following
engraftment of lung cancer tissue in immunodeficient mice, Yasuda
and co-workers identified TiBc producing tumor specific Abs
against mutated p53 [13]. Thus, at least a proportion of TiBc
accumulating in solid tumors can produce tumor antigen specific
antibodies. TiBc could consequently be helpful for the identification
of novel or at least of relevant tumor specific antigens (TSA).
Despite the obvious importance of B cells in immunological
circuits, the functional role of TiBc was so far not examined in detail.
This may be attributable to the difficulties in obtaining sufficient cell
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overcome this obstacle, we designed a direct and reproducible
method to generate immortalized B cell lines from primary tumor
tissues. We used EBV-transformation by culturing B cells in the
presence of virus-containing supernatant of the marmoset cell line
B95/8 [14]. Clonality of outgrowing TiBc cultures, isotypes and
function of secreted immunoglobulins (Ig) were analyzed.
Materials and Methods
Tumor specimens
Resection specimens of primary CRC without prior chemo- or
radiotherapy (n=19) were received fresh from surgery. Prior
written informed consent was obtained from all patients, and all
procedures were approved by the Ethics Committee of the
University of Rostock (reference number II HV 43/2004) in
accordance with generally accepted guidelines for the use of
human material.
Molecular classification was done according to [15]. These data
as well as staging information compiled from the clinical charts are
summarized in Table 1.
Tumor cell lines and culture media
CRC cell lines HROC24 (MSI, Kras
wt, Braf
mut) and HROC46
(MSS, APC
mut, Kras
mut, Braf
wt), were established in our lab from
resection specimen [16]; HCT116 cells were originally obtained
from ATCC, Rockville, MD, USA. Cells were maintained in
culture medium (DMEM/HamsF12 supplemented with 10% fetal
calf serum (FCS), glutamine (2 mmol/l) and antibiotics (penicillin/
streptomycin/gentamycin)).
Generation of TiBc cultures from primary tumors
Tumor fragments were cut into small pieces and homogenized.
Cell suspensions were obtained following nylon passage. Either a
total of 5610
6 cells were cultured in a cell culture flask or cells
were distributed in one 48-well plate in the presence or absence of
EBV-containing supernatant of B95/8 cells. To prevent T and
NK cell growth, cyclosporin A (5.5610
27 M) was added.
Typically, outgrowth of TiBc cultures was observed after a period
of 4–8 weeks. Established TiBc were harvested, expanded and
further characterized. All cell culture reagents were obtained from
PAA (Co ¨lbe, Germany), antibiotics and antifungal agents were
from the pharmacy of the university hospital Rostock.
Clonality analysis of TiBc
Genomic DNA was extracted from pelleted TiBc cultures with
the Qiagen extraction kit (Hilden, Germany). Clonality was tested
using the BIOMED-2 multiplex PCRs protocols to detect Ig gene
rearrangements with Genescan detection [17]. Denatured PCR
products are size separated in a denaturing capillary sequencing
polymer and detected via automated scanning with a laser.
Monoclonal cell samples will give rise to PCR products of identical
size (single peak), whereas in polyclonal samples many different
IGH PCR products will be formed, which show a characteristic
Gaussian size distribution.
Histological and immunohistochemical assessment of
TiBc
Peritumoral lymphocytic infiltration patterns were assessed by
routine H&E staining. Additionally, representative paraffin-blocks
Table 1. Data of colorectal carcinomas used for generation of TiBc bulk cultures, flow cytometry of CD19
+CD20
+ B cells from
primary tumors and overall results of outcomes.
Tumor-ID Age/Gender Site TNM-Stage Molecular type TiBc culture
B cells in primary
CRC [%]
HROC56 70/m right colon G1T3N0M0 ND failure ,0.1
HROC57 43/m right colon G3T3N2M1 neuroendocrine success 0.7
HROC59 76/m right colon G2T3N1M1 spStd success 3.0
HROC60 71/m right colon G2T2N0M0 CIMP-H success 3.0
HROC61 57/m rectum G3T3N0M0 spStd success NA
HROC62 84/f right colon G3T4N2M0 spStd failure 4.1
HROC63 81/f left colon G2T4N0M0 spStd failure NA
HROC64 71/m left colon G2T2N0M0 spStd failure NA
HROC66 75/m rectum G2T3N2M0 spStd success ,0.1
HROC67 54/m left colon G2T3N1M0 spStd success NA
HROC68 84/m left colon G2T4N2M0 spStd success NA
HROC69 62/m right colon G3T3N0M1 spStd success 1.1
HROC71 52/m right colon G2T3N0M0 HNPCC { ,0.1
HROC83 85/f right colon G2T3N1M1 spStd { NA
HROC84 88/f left colon G2T3N0M0 spStd { 0.6
HROC85 65/m rectum G2T3N0M0 spStd success NA
HROC86 79/f left colon G2T3N1M0 spStd success ,0.1
HROC87 76/f left colon G3T3N0M0 spMSI failure NA
HROC90 84/f rectum G2T2N0M0 ND success 1.9
NA – not analyzed;
{- no long-term culture established;
ND – not yet determined.
doi:10.1371/journal.pone.0032639.t001
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bodies directed against CD3, CD20, CD79a, and CD21 using
standard protocols.
Flow cytometric phenotyping
Activation and differentiation status of TiBc were traced by flow
cytometry using the following FITC-, PE or APC-conjugated Abs:
CD3, CD19, CD20, CD23, CD38, CD27, CD80, MHC I
(Immunotools, Friesoythe, Germany), CD83, CD138, and MHC
II (Miltenyi Biotec, Bergisch-Gladbach, Germany). Samples were
analyzed on a FACSCalibur Cytometer (BD-Biosciences, Heidel-
berg, Germany). Data analysis was performed using CellQuest
software (BD-Biosciences).
HIg- and Cell-ELISA
Ig isotype production of TiBc was quantified by ELISAs specific
for IgG, IgA, IgM, IgD and IgE (Bethyl Laboratories, Montgom-
ery, TX, USA). Briefly, ELISA plates were coated with anti-
human Ig (50 mg/ml; 4uC), washed and blocked. TiBc superna-
tants (1:50; collected for a period of six month) were added, bound
Ig was detected with horse-radish-peroxidase-conjugated anti-
human Ig (1:50.000), and visualized by 3.3.5.5-Tetramethylbenzi-
din. Reactions were stopped using 2 M H2SO4. Absorbance was
measured on an ELISA plate reader at 450 nm (reference
620 nm). Ig concentrations were determined by comparison with
a standard curve generated from serial dilutions of Ig standards.
For Cell-ELISA, 96-well plates, seeded with fixed tumor cells,
were used. All washing and blocking steps were done as described.
One mg/well IgG was added and incubated at room temperature
(2 h). Therapeutic Abs Cetuximab
TM (anti-EGFR) and Trastuzu-
mab
TM (anti-Her2/neu) served as positive, Rituximab
TM (anti-
CD20) as negative controls. As a measure for IgG tumor cell
binding, extinctions from the background (medium alone, ,0.20)
were subtracted.
In vitro Binding assays
CRC cell lines (0.5610
6) were fixed in 4% formalin for 30 min
and incubated with IgG-supernatants from several TiBc cultures
(1 mg/ml; 1 h; 4uC). Therapeutic control Abs were applied as
described. After washing, cells were stained with secondary anti-
human IgG-FITC conjugated Ab (1:40). Data acquisition was
done as described.
Immunofluorescence was performed with fixed tumor cells
followed by blocking (2% BSA; 1 h) and incubation with IgG-
supernatants from selected TiBc clones (1 mg/ml, 2 h). Afterwards,
Alexa 546-conjugated anti-human IgG (1:100, 1 h) was applied.
Cell nuclei were counterstained with DAPI. Tumor cell binding
was visualized by fluorescence microscopy (Leica DM 4000 M;
Leica Wetzlar, Germany). Pictures were obtained using the
provided evaluation software (Leica Image Pro Plus 6.0 image
analysis software).
Statistics
Statistical differences were determined by using the two-sided
Fisher’s exact T-test. The tests were performed with Sigma-Stat
3.0 (Jandel Corporation, San Rafael, CA, USA). The criterion for
significance was taken to be p,0.05.
Results
Patterns of lymphocytic infiltration
TiBc were observed to concentrate in the stroma at the invasive
margin, and they were never seen between the epithelia of the
neoplastic glands (Figure 1A, B). Distribution of TiBc, tumor-
infiltrating CD3
+ T cells, as well as mature plasma cells was quite
heterogeneous, even within a single tumor (Figure 1 C, D). In
addition, at the invasive margin follicular aggregates of TiBc
residing in a mesh of follicular dendritic cells were seen (Figure 1E,
inset), and these varied in frequencies between cases.
Generation of EBV-transformed TiBc cultures
Establishment of TiBc bulk cultures was attempted by EBV
transformation for 19 tumors (Table 1). Initially, we generated 14
TiBc bulk cultures (74% success rate) but permanent growth could
not be obtained in three cases. However, the remaining 11 cultures
proceeded to grow continually. In these, a characteristic in vitro
pattern of follicular aggregates was observed – similar to
peripheral EBV-transformed B cells. Success in obtaining cultures
did not correlate with density or pattern of lymphocytic infiltration
of the primaries. Moreover, it was quite independent from the
amount of TiBc harvested upon initial isolation (Table 1).
However, due to the technical challenge of FACS analysis from
primary tumor tissue, those data on CD19
+CD20
+ B cells in
primary CRC need to be interpreted with caution.
To sum up these findings, this method circumvents problems
implicated with low B cell numbers obtained by isolation from
fresh primary tumors and the technical demands of handling
freshly isolated TiBc [11].
TiBc cultures are of clonal origin
Clonality analysis for IGH and IGK gene rearrangement was
performed from the 11 TiBc bulk cultures. Comparison of V(D)J
Figure 1. Tumor-infiltrating lymphocytes in a primary colorec-
tal carcinoma (HROC60) highlighted by immunohistochemis-
try. (A, B) TiBc are observed to concentrate in follicular aggregates at
the invasive margin. (C, D) Diffuse T cell infiltration within tumor stroma
and to a minor extend within neoplastic glands given by positive
staining for CD3. (E) TiBc in follicular aggregates (arrows) reside in a
mesh of follicular dendritic cells (inset). Original magnification (A, C, E)
46and (B, D) 206.
doi:10.1371/journal.pone.0032639.g001
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clonality in each of the established culture. By applying Gene
Scanning fragment-length PCR, predominant clonal rearrangement
(monoclonality) was identified as a single peak consisting of one type
ofPCRproduct(exemplaryresultsaregiveninFigureS1A).Analysis
of early passages of the cultures demonstrates, however, oligoclonal
junctional mutation patterns and thus implies that monoclonality is
the result of continuous in vitro selection (Figure S1B).
Equally important, demonstration of monoclonality for all of the
long-term cultures forms the basis for TiBc characterization and
applying Abs produced thereof for functional analysis.
TiBc are of mature immunophenotype
The most interesting result was the high expression of the B cell
maturation marker CD23, suggesting growth after antigenic
stimulus (Table 2). Consistent with ongoing maturation, in each
clone a heterogeneous pattern of B and plasma cell markers was
observed (Table 2). Expression of the general activation marker
CD83 ranged from zero to 60%. None of the clones expressed T
cell markers confirming their B lymphoid origin. Expression of
MHC class I and II molecules as well as the co-stimulatory
adhesion molecule CD80 was very high.
Ig repertoire produced by TiBc clones
All of the analyzed supernatants contained detectable, though
varying levels of either one of the three main Ig isotypes: IgG, IgM
or IgA (Table 2). Production of IgD or IgE was not observed in
any of the cultures. The pattern of Ig secretion did not alter during
the observation period. Importantly, among the 11 cultures that
had been included into the analysis, exclusive production of IgG
was found in 55% (6/11 cultures).
IgGs specifically bind to tumor cells
Of the five TiBc-derived IgGs included into these analyses, four
were observed to bind to HCT116 and three to HROC24 and
HROC46 (Table 2) in initial cell ELISA screenings. Of note, the
affinities of TiBc-produced IgGs were comparable to or even
higher than those of the therapeutic Abs specific for EGFR and
Her2/neu. These two Abs were chosen as positive controls due to
their high expression on the analyzed cell lines (each 80–100%,
Figure 2A).
Specific allogeneic tumor cell recognition was confirmed for
three of the IgGs by flow cytometry (Figure 2B). IgG from
TiBcHROC66 and TiBcHROC90 exhibit strong avidity towards
all cell lines tested and both bound to .90% of the tumor cells.
Likewise, the mean fluorescence intensity, representing the
number of bound Ab molecules per cell, differed only marginally
between cells (data not shown). TiBcHROC57-derived IgG
displayed an intermediate binding affinity with a maximum of
15% staining for HROC46 cells. When analyzing the other IgGs,
weak tumor cell binding if any was observed. Less than 5% of
tumor cells allowed binding of IgG from TiBcHROC59, 68, and
86 (Figure 2A).
Finally, immunofluorescence studies were done for further
confirmation of the above findings and to get an idea of the
cellular antigen distribution. Tumor cell recognition was specific,
and this was most pronounced for supernatants from TiB-
cHROC66 and 90. Both IgGs bound to HCT116 cells with high
affinity (Figure 3, upper panel). Target cell staining with
TiBcHROC57-derived IgG was weaker, but still specific and
mostly intracellular (Figure 3, middle panel). Again, negligible
staining was shown for TiBcHROC68-derived IgG. Similar
observations were made for HROC46 with highest binding for
IgG from TiBcHROC66 and TiBcHROC90. TiBcHROC57-
derived IgG bound tumor cells to a lesser extent. Positive staining
was shown for some, but not all tumor cells (Figure 3, lower panel).
No evidence for latent EBV-transformation in vivo
Growth of lymphoblastoid tumors occasionally complicates
xeno-transplantation of tumors in mice [18]. This gave rise to the
Table 2. Immunophenotypes of TiBc clones by flow-cytometry and results of Cell ELISAs.
ID of primary
CRC Immunophenotype [% positive cells] Ig-type Cell ELISA [Ex 495 nm]
CD19 CD20 CD23 CD27 CD80 CD83 CD138 MHC I MHC II HROC24 HROC46 HCT116
HROC57 57 17 90 0 78 23 46 98 100 IgG 0.55 0.44 0.20
HROC59 14 17 95 17 75 0 13 94 98 IgG ,0.1 ,0.1 NA
HROC60 24 3 44 8 48 22 22 97 100 IgM NA NA NA
HROC61 33 20 65 2 34 19 19 100 100 IgM NA NA NA
HROC66 50 9 89 5 70 1 49 93 100 IgG ,0.1 ,0.1 0.50
HROC67 57 17 90 0 78 21 46 98 100 IgM NA NA NA
HROC68 35 5 92 1 46 8 65 94 100 IgG 0.28 0.37 0.67
HROC69 56 39 96 17 22 21 51 99 100 IgA NA NA NA
HROC85 64 20 80 0 86 59 11 98 100 IgM NA NA NA
HROC86 NA 37 40 38 31 0 55 52 99 IgG NA NA NA
HROC90 91 26 53 1 84 35 48 93 100 IgG 0.39 0.53 0.89
Cetuximab 0.40 ,0.1 0.26
Trastuzumab 0.33 0.15 0.50
Rituximab ,0.1 ,0.1 ,0.1
Flow cytometric analysis of established EBV-transformed TiBc cultures (after four to five month in culture). ELISA was performed with the use of supernatants from 11
TiBc clones to determine their hIg isotypes (monitored for a period of six months). NA – not analyzed. Results show data from one representative experiment each
performed at least three times in triplicates.
doi:10.1371/journal.pone.0032639.t002
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hide in the immunosuppressive environment of human CRCs to
escape EBV-specific T cells [18].
Our in vitro system provided a perfect basis to test this
hypothesis. TiBc cultures from another 12 CRC were cultured
in the presence or absence of EBV (Table 3). There was no
outgrowth in any of the cultures without exogenous EBV, whereas
with EBV, a total of 97 TiBc clones was obtained from 10/12
cases. Additionally, this simple procedure facilitates the generation
of several TiBc clones from one tumor specimen.
Discussion
In various human cancers, CRC among them, the degree of
lymphocytic tumor infiltration correlates with patients’ clinical
course. Previous studies largely focussed on T cells [5,6]. Besides, a
few preliminary studies described the positive impact on systemic
humoral immune responses not only for early detection but also
for cancer immunotherapy [19,20]. We here began to elucidate
the role of the humoral anti-tumor immune response within the
tumor microenvironment. First, by EBV-transformation we were
able to generate long-term monoclonal B-cell lines from TiBc.
This procedure was comparatively easy to carry out and quite
efficient, yielding 11 lines from 19 CRC specimens. We wish to
point out, that this protocol, backed up by proof of monoclonality
by the BIOMED protocols used in the diagnostics of lymphomas,
offers itself as a basis to start from for any researchers working in
this field. It circumvents efficiently the problems implicated in
handling fresh TiBc isolates that often are very low in numbers.
The mature immunophenotype of TiBc from primary CRC
observed in this study suggests activation and antigen-induced
maturation, making accidental tumor tissue infiltration quite
unlikely. In agreement with these observations, B cells infiltrating
human breast carcinoma tissues were shown to undergo antigen-
driven proliferation, somatic hypermutation and affinity matura-
tion, thus representing a tumor specific humoral immune response
[11]. This interpretation is further supported by the fact that, as
seen by immunohistochemistry, in CRC the great majority of TiBc
resides in follicular aggregates. Likewise, peritumoral follicular
aggregates of lymphocytes have long ago been reported as
‘‘Crohn’s like reaction’’. This positive prognosticator for CRC
was interpreted as an immune-mediated anti-tumor effect [21,22].
Most of the TiBc cultures started to produce IgG directly after
cultivation, IgA secretion was found in one case. Beside IgG, IgA is
known to be the other main isotype, secreted exclusively by B cells
following a specific stimulus, and this provides a further argument
for our hypothesis that B cell infiltration into the tumors is not
accidental. Unraveling the functional capacity of this IgA will be of
great interest, however in this work we focused on IgG-secreting
TiBc cultures. IgG is generally considered to have the greatest
potential for therapeutic purposes, because it is most efficient in
mediating complement- or NK cell-mediated tumor cell lysis, and
has an extended plasma half life [23–26].
Using functional assays, specific binding to tumor cells was
demonstrated especially for two of the IgGs (from TiBc66 and
TiBc90). Both intra- and extracellular antigens were recognized
and since all binding experiments were performed in allogeneic
settings, these antigens must be shared between different tumor
cells. These findings are in line with and add to reports on TSA by
other groups [11,12,27]. Investigations to identify the antigens
bound by TiBc-derived IgGs at the molecular level are on their
way, and we are confident that this will help to understand the
process of CRC immunoediting [28].
High expression of MHC class I and II molecules as well as the
co-stimulatory adhesion molecule CD80 is another interesting
finding in this study. This suggests a role for TiBc not only as
producers of tumor-specific Abs but also as local APCs, potentially
modulating T cell restricted immune responses. One might
speculate that tumor-antigen specific TiBc constitute highly
efficient APC especially when compared with antigen-unexper-
ienced circulating B cells. However, recruitment of TSA-specific B
cells (namely regulatory B cells) by tumor cells in order to suppress
antitumoral T cells in situ is also imaginable [29].
Figure 2. In vitro binding assay. (A) Histograms show HCT116 tumor cells following incubation in secondary FITC-conjugated Ab only (black
curves), therapeutic Abs (green curves, upper panel) or TiBc-derived IgGs (green curves middle and lower panel). Representative experiments each
performed in triplicates are shown. (B) Quantitative analysis for flow cytometric assessment of TiBc-derived IgG binding capacity towards tumor cell
targets (HROC24, HROC46, and HCT116). As positive control, fixed cells were stained with therapeutic Abs Cetuximab and Trastuzumab. Negative
controls consisted of fixed tumor cells either stained with Rituximab or the secondary FITC-conjugated Ab only.
doi:10.1371/journal.pone.0032639.g002
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PLoS ONE | www.plosone.org 5 February 2012 | Volume 7 | Issue 2 | e32639Figure 3. Representative immunofluorescence images of tumor cells showing positive binding of both membranous as well as
intracellular target structures by TiBc-derived IgGs. (A) HCT116 and (B) HROC46 tumor cells were stained with TiBc-derived IgGs and Alexa
546-conjugated anti-human IgG. Cell nuclei were counterstained with DAPI. Therapeutic antibodies Cetuximab and Rituximab served as positive and
negative control, respectively. Original magnification 640.
doi:10.1371/journal.pone.0032639.g003
Table 3. Data of colorectal carcinomas used for generation of TiBc cultures with and without EBV, percentage of CD19
+CD20
+ B
cells from primary tumors (flow cytometry), and outcomes.
Tumor-No. Age/Gender TNM-Stage B cells in primary CRC [%] +EBV 2EBV
No. of clones No. of clones
1 65/f G3T4N1 0.6 4 0
2 61/m G2T3N2 4.4 12*** 0
3 69/m G2T3N0M0 ,0.1 9** 0
4 80/f G2T4N0M0 0.5 10*** 0
5 58/m G2T3N0M0 ,0.1 4 0
6 72/m G2T3N2M1 0.8 11*** 0
7 80/m G2T3N0M1 2.4 9** 0
8 60/m G2T3N2 0.2 3 0
9 82/m G2T2N0M0 NA 0 0
10 74/m T3N2M1 ND 24*** 0
11 88/f G1-G3T3N0M0 ,0.1 11*** 0
12 78/f G2T3N2M1 NA 0 0
A total of 5610
6 cells were distributed in one 48-well plate in the presence (24 wells) or absence (24 wells) of EBV-containing medium. The cells were maintained in a
humidified 37uC incubator with 5% CO2. NA – not analyzed. ND – could not be correctly determined.
**p,0.01;
***p,0.001; Fisher’s exact T-test.
doi:10.1371/journal.pone.0032639.t003
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production of low-affinity, unstable IgM [30]. Since isotype switch
during long-term culture was not observed in any of the TiBc
cultures, we consider it most likely that our cases of TiBc IgM
production (n=4) are a primary antigen-driven immune response
and not induced by EBV transformation. It will be of interest to
analyze, if stimulation of the IgM-producing TiBc with autologous
T helper cells will induce Ig class switching, possibly leading to the
production of highly affine IgG. Secondly, since tumor-specific
IgM antibodies have been described, specific recognition of tumor
structures may be anticipated [31–33].
The major findings of our study may be summarized as follows:
(a) human CRCs harbor B cells (i.e. TiBc) that can be long-term
cultured subsequent to EBV-immortalization; (b) TiBc harvested
from these are antigen-experienced and secrete Ig of the three
main Ig isotypes (IgG, IgA, IgM) in amounts sufficient for
functional studies; (c) IgG derived from several TiBc clones
strongly bind to antigenic structures present on several allogeneic
tumor cell lines; and (d) TiBc show no evidence for latent EBV-
infection in vivo.
On the basis of these novel findings, Ig-producing long-term
TiBc cultures may provide a convenient cellular tool for the
identification of novel or relevant TSA.
Supporting Information
Figure S1 Clonality analysis using the BIOMED-2
multiplex PCRs protocols to detect Ig gene rearrange-
ments with Genescan detection. (A) IGH and IGK gene
rearrangement from selected TiBc cultures giving rise to PCR
products of identical size (single peak). This confirms monoclon-
ality of TiBc cultures. Monoclonal B-LCLs were taken as control.
(B) Exemplary data for early passage TiBcHROC68 culture.
Oligoclonality was detected by different PCR products indicating
the presence of several subclones at early culture.
(TIF)
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